FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The compliance rate for completion of FACT-P and EQ5D at all treatment phase assessment visits was 92% (range 92-100%). Group means at baseline for FACT-G (APA, 83; PBO, 84; out of a total score of 108) and were consistent with the FACT-G population norm of (mean: 81) for adult men. Median treatment exposure was: APA, 16.9 mo; PBO, 11.2 mo. Mean change from baseline in FACT-P total and subscales was generally not significantly different over time comparing APA vs PBO. Any significant differences represented better scores for APA. No significant differences were observed comparing APA vs PBO in time to degradation analyses in FACT-P total and subscale scores. Overall, FACT-G and other PRO scores were maintained with APA and ADT from initiation of treatment (Figure below).
In conclusion, baseline HRQoL data suggest that men with nmCRPC have similar HRQoL to the general population. The addition of APA to ADT maintained HRQoL and significantly improved MFS in this patient population, who are largely asymptomatic at baseline.
Presented by: Eric J. Small, MD, UCSF Helen Diller Family Comprehensive Cancer Center
Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre @GoldbergHanan at the 2018 AUA Annual Meeting - May 18 - 21, 2018 – San Francisco, CA USA
Further Related Content:
Eric J. Small, MD 2018 AUA Presentation Results from SPARTAN: PSA Outcomes in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide
Watch: First presentation of SPARTAN - a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) - Eric Small
Watch: M0 CRPC Outcomes in the Use of New Androgen Receptor-Targeted Therapies - A Conversation with Charles Ryan and Alicia Morgans
Watch: The Incredible Shrinking M0 CRPC - Phillip Koo